• US: +1 9176726599
  • Login

Gene Delivery Technologies Market Status (2017-2021) and Forecast Market Analysis, Regional Outlook, Segment Growth Potential, and Competitive Market Share Analysis, 2022-2028

Format: PDF | Pages: 367 | Report ID: MRS1187


Report Description

The global Gene Delivery Technologies market was worth USD 2,700.4 million in 2021 and is expected to be worth USD 3,502.7 million by 2028, growing at a CAGR of 14.8% between 2022 and 2028.

Integrating genetic material, that is, DNA or RNA, into the system of cellular gene regulation to resolve the expression of a defective gene.

Market Trends

The development of cell and gene treatments has not only revolutionized the treatment of hereditary and incurable diseases but has also had a significant impact on transforming the entire pharmaceutical ecosystem. By the end of 2019, over 27 cell and gene therapies had been launched globally, and about 990 companies were involved in advanced therapy R&D and commercialization. One of the primary driving forces in the market for gene delivery technologies is the continually developing landscape of sophisticated medicines. Due to innovations in nanotechnology and physical technology, sophisticated physical gene delivery technologies like magnet operation, sonoporation, and electroporation have been intensively researched. These approaches are gaining popularity due to their advantages such as their briefness and nontoxicity. These factors are expected to increase the utilization of items available in this market, consequently fueling organic revenue growth for operational companies.

In addition, the expanding continuous research and development in the field of genomics around the world have further fueled the expansion of the market under consideration. Chronic diseases are the leading cause of death in underdeveloped countries.

Segmentation Insights

In terms of delivery systems, the industry is categorized into Non-viral Gene Delivery, Viral Gene Delivery Systems, and Combined Hybrid Delivery Systems.

Adenovirus system, lentivirus vector, retrovirus vector, herpes simplex virus vector, Sendai virus vector, adeno-associated virus vector, and others are all types of viral gene delivery systems. Natural organic chemicals, physical procedures, and chemical ways are all part of the non-viral gene delivery system. The viral gene delivery technology segment dominates the global gene delivery system market in terms of revenue. The segment is driven by an increase in demand for viral gene delivery systems for the treatment of hereditary and acquired disorders caused by gene insertion or deletion. Only a limited portion of the industry is devoted to integrated hybrid delivery systems.

The market is bifurcated into Oncology, Infectious Diseases, Cardiovascular Disorders, Diabetes, Pulmonary Disorders, CNS, and Others based on application.

The oncology segment dominates the global gene delivery technology market in terms of revenue. The global gene delivery technology market is being driven by an increase in cancer incidence across all regions. According to the WHO study (2017), cancer accounts for around one-sixth of all deaths worldwide. CNS is the market's second-largest category, driving growth. By 2025, the category is expected to be driven by an increase in the prevalence of neurological illnesses. According to EurekAlert, neurological illnesses are a primary cause of death worldwide. Diabetes is a chronic condition that affects the majority of the world's population. According to a WHO estimate, diabetes accounted for around 1% of all fatalities in Japan in 2016.

Competitive Insights

The increased interest of public and private investors in gene delivery technologies is expected to hasten the entry of new enterprises into the market. Furthermore, current significant players are introducing numerous strategic steps to increase their market position, such as acquisitions and mergers, collaboration, and licensing. In recent years, the worldwide gene delivery technologies industry has seen some major acquisitions and mergers.

For instance, in May 2020, Merck announced the acquisition of Themis, a developer of vaccines and immunomodulation medicines, to strengthen its vaccine development capabilities for the SARS-CoV-2 vaccine program.

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

  • F. Hoffmann - La Roche AG
  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • Horizon Discovery Group Co.
  • OriGene Technologies, Inc.
  • Oxford Biomedica
  • SignaGen Laboratories
  • Vectalys
  • Takara Bio Inc.
  • Bio - Rad Laboratories, Inc.
  • System Biosciences LLC
  • Catalent Inc.
  • Promega Corporation
  • Agilent Technologies
  • Sirion - Biotech GmbH

Delivery System Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Viral Gene Delivery Systems
  • Non-viral Gene Delivery
  • Combined Hybrid Delivery Systems

Application Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • Oncology
  • Infectious Diseases
  • Cardiovascular Disorders
  • Diabetes
  • Pulmonary Disorders
  • CNS
  • Other Applications

Route of Administration Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • Oral
  • Injectable
  • Nasal
  • Other Routes of Administration

Region Coverage (Regional Consumption, Demand & Forecast by Countries, etc.):

  • North America (U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain etc.)
  • Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
  • South America (Brazil, Mexico, Argentina etc.)
  • Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa etc.)

Frequently Asked Questions

The global Gene Delivery Technologies market was worth USD 2,700.4 million in 2021 and is expected to be worth USD 3,502.7 million by 2028, growing at a CAGR of 14.8% between 2022 and 2028.
North America captured the highest revenue in 2021 and is projected to continue its dominance during the study period.
The global Gene Delivery Technologies market is expected to be worth USD 3,502.7 million by 2028, growing at a CAGR of 14.8% between 2022 and 2028.
Asia Pacific (especially China, and India) region is projected to grow at the fastest growth rate during the study period.
The increased interest of public and private investors in gene delivery technologies is expected to hasten the entry of new enterprises into the market. Furthermore, current significant players are introducing numerous strategic steps to increase their market position, such as acquisitions and mergers, collaboration, and licensing. In recent years, the worldwide gene delivery technologies industry has seen some major acquisitions and mergers.

Why Choose Market Research Strategy?

  Authenticated Data Sources

We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports

  Express Delivery

We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround

  Gain Instant Access

Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.

  Our Pledge to You

We abide by the information security policy and adheres to keep your private and business information confidential and secure.

Copyright © 2022 Market Research Strategy, All rights reserved.